Monte Rosa Therapeutics, Inc.
GLUE
$3.70
-$0.34-8.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 248.92% | 156.32% | 21.28% | 5.19% | 3.86% |
| Total Depreciation and Amortization | 3.40% | -5.25% | 19.60% | -16.20% | 38.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.30% | 26.22% | -19.17% | -19.88% | 23.69% |
| Change in Net Operating Assets | -189.95% | 4,610.53% | 16.89% | 77.32% | -122.35% |
| Cash from Operations | -135.29% | 714.09% | 24.39% | 27.24% | -228.79% |
| Capital Expenditure | -767.21% | 54.14% | 80.27% | -46.10% | 18.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -221.17% | -180.51% | 164.51% | -626.26% | -29.71% |
| Cash from Investing | -224.41% | -181.85% | 161.72% | -720.70% | -31.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.61% | 23,953.33% | -99.97% | 19,682.11% | -14.88% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -- | -- |
| Cash from Financing | -97.70% | 3,953.33% | -99.98% | 39,746.75% | -99.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -247.72% | 488.16% | 84.33% | 132.42% | -140.61% |